Erasca, Inc.

NASDAQ: ERAS · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001761918Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 59DQ —GM —SS 58

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, market scale · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$124.5M

Employees

103

as of 2026-08-07

Market cap

$6.3B

as of 2026-08-07

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$124.5M-$124.5M2025

Operating income-$140.9M-$140.9M2025

Total assets$396.2M$396.2M2025

Liabilities$71.0M$71.0M2025

Equity$325.2M$325.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Erasca, Inc.’s financial profile?

Erasca, Inc. earned -$124.5M in FY2025 net income.

Peers · Healthcare

Immunovant, Inc.——Vaxcyte, Inc.——Belite Bio, Inc——Definium Therapeutics, Inc.——Dyne Therapeutics, Inc.——Edgewise Therapeutics, Inc.——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEOJonathan E. Lim

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: ERAS

Employees103

IPO date2021-07-16

Latest filings

8-K2026-08-24 10-Q2026-08-11 8-K2026-08-11 8-K2026-08-10 8-K2026-07-14 8-K2026-07-13 8-K2026-07-01 8-K2026-05-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.